Next Generation Diabetes Therapy and Drug Delivery Market Expected to Reach $9,673 Million, Globally, by 2023 - Allied Market Research - Seite 2

CGM system is a well-established product and dominates the market, attributed to the presence of a large patient base suffering from diabetes with highest share in 2015, and is anticipated to continue this trend in the future, in terms of revenue. Advantages of these systems as compared to conventional diabetic products are ease of usage and efficient & early detection of change in blood glucose levels, which are expected to boost the growth of this segment.

Diagnostics/clinics was the highest contributor and is anticipated to continue its dominance during the analysis period, and has accounted for about half of the share of the global market in 2015, due to the increase in procurement of the products from diagnostics and clinics by diabetic patients.

In 2015, North America displayed maximum contribution to the total revenue generated, while Asia-Pacific is expected to witness the highest CAGR of 50.2%, due to rise in disposable income, improvement in healthcare expenditure, and increase in adoption rate of advanced diabetic products.

Request for Customization @ https://www.alliedmarketresearch.com/request-for-customization/2098

KEY FINDINGS OF THE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET STUDY: 

• Artificial pancreas segment is projected to grow at the highest rate during the analysis period.
• CGM system was the highest revenue-generating segment, and is expected to continue its dominance in future.
• North America dominated global next generation diabetes therapy and drug delivery market, and is projected to grow at a CAGR of 40%.
• India is expected to grow highest in the Asia-Pacific region, registering a CAGR of 51.1%.
• Diagnostic/clinic segment was the highest end user contributor towards the market during the analysis period.

According to Sriram Radhakrishnan, Team Lead, Healthcare at Allied Market Research, "The comfort and efficiency offered by next generation diabetes products is expected to attract the patients with higher purchasing power and fuel the innovations and market growth."

Do Enquiry before purchasing Report @ https://www.alliedmarketresearch.com/purchase-enquiry/2098

The key companies profiled in the report include Abbott Laboratories, Medtronic, Inc., Sanofi, Novo Nordisk, MannKind Corporation, Enteris BioPharma, Dexcom, Inc., Senseonics Holding, Inc., Medtech, and Johnson & Johnson.